SCHEMBL15084341

SCHEMBL15084341

CC1CC2CCC(C1)N2Cc1c(F)cccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.58
OPRD1 P41143 3/20 0.58
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ABCB1 P08183 1/20 0.36
EED O75530 1/20 0.36
CYP3A4 P08684 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
SLC6A2 P23975 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL807317 0.83 OPRM1 (0.54) OPRM1OPRD1KDM4EALDH1A1POLB
SCHEMBL807487 0.81 OPRM1 (0.55) OPRM1OPRD1KDM4EALDH1A1POLB
SCHEMBL806942 0.81 OPRM1 (0.55) OPRM1OPRD1KDM4EALDH1A1POLB
SCHEMBL15084343 0.78 OPRM1 (0.46) OPRM1OPRD1KDM4EALDH1A1POLB
SCHEMBL807652 0.75 SIGMAR1 (0.47) OPRM1OPRD1MAPK1SMN1; SMN2ABCB1
SCHEMBL15082028 0.75 OPRM1 (0.47) OPRM1OPRD1EEDDRD2DRD4
SCHEMBL15014563 0.74 CHRM2 (0.58) OPRM1OPRD1ALDH1A1MEN1KMT2A
SCHEMBL4530898 0.74 CHRM2 (0.58) OPRM1OPRD1ALDH1A1MEN1KMT2A
SCHEMBL15084365 0.72 HRH3 (0.51) KDM4EALDH1A1POLBTSHRMAPK1
SCHEMBL15084313 0.71 MAPK1 (0.42) OPRM1OPRD1KDM4EALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MAPK1, MAPK3, MAP3K1 OPRM1 3387/4885OPRD1 2021/4885KDM4E 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.